Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this trial is to study the effect of Human Papillomavirus (HPV) vaccination on the elevation of antibody titer to 4 serotypes of HPV in patients with systemic lupus erythematous and compare the antibody response with an equal number of age-matched healthy women.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tuen Mun Hospital
• Treatments: Vaccines

Criteria

Inclusion Criteria:

SLE patients

• Female patients aged ≤ 35 years

• Fulfilling the American College of Rheumatology (ACR) criteria for the classification of SLE

• Having received a stable dose of prednisolone and/or other immunosuppressive agents within 3 months of study entry

• Able to give written informed consent

Controls

• Women aged ≤ 35 years, matched those of SLE patients recruited

• No known chronic medical diseases

• Not receiving any long-term medications including herbs

Exclusion Criteria:

• History of allergy to HPV vaccines